Key Events This Week
2 Feb: Stock opens week at Rs.380.05 amid broad market weakness
3 Feb: Strong rebound with 6.33% gain to Rs.404.10
4 Feb: Intraday low hit at Rs.366.35 amid price pressure and margin concerns
5 Feb: Recovery with 6.63% gain to Rs.407.95 following stabilised quarterly results
6 Feb: Intraday high of Rs.445 and 7.4% surge closes week at Rs.431.80

TruAlt Bioenergy Ltd Hits Intraday High with 7.4% Surge on 6 Feb 2026
2026-02-06 15:48:18TruAlt Bioenergy Ltd recorded a robust intraday performance on 6 Feb 2026, surging 7.4% to touch a day’s high of Rs 445, significantly outperforming the Commodity Chemicals sector and broader market indices.
Read full news articleAre TruAlt Bioenergy Ltd latest results good or bad?
2026-02-04 19:24:35TruAlt Bioenergy Ltd's latest financial results for Q3 FY26 present a complex picture of operational performance. The company achieved a notable revenue growth of 520.96% quarter-on-quarter, reaching ₹713.24 crores, which reflects a strong recovery in demand within the commodity chemicals sector. Year-on-year, revenue also grew by 71.82%, indicating a positive trend in sales performance compared to the previous year. However, this significant top-line growth did not translate into proportional profitability. The net profit for the quarter was reported at ₹69.33 crores, which, while representing a substantial quarter-on-quarter increase of 282.74%, showed a decline of 7.79% compared to the same quarter last year. This suggests that despite higher sales, the company's ability to convert revenue into profit has weakened. The operating margin for TruAlt Bioenergy has come under pressure, decreasing to 18.79% ...
Read full news article
TruAlt Bioenergy Reports Stabilised Quarterly Performance Amid Margin Pressures
2026-02-04 11:00:20TruAlt Bioenergy Ltd has reported a flat financial performance for the quarter ended December 2025, signalling a stabilisation after a period of negative trends. While revenue and profitability metrics have shown notable growth compared to the previous four-quarter averages, recent margin pressures and subdued six-month PAT growth highlight ongoing challenges for the commodity chemicals player.
Read full news article










